{"id":4966,"date":"2025-04-04T16:01:04","date_gmt":"2025-04-04T13:01:04","guid":{"rendered":"https:\/\/www.revitalizeinturkey.com\/\/?p=4966"},"modified":"2026-05-21T19:30:27","modified_gmt":"2026-05-21T19:30:27","slug":"alzheimer-blood-test","status":"publish","type":"post","link":"https:\/\/revitalizeinturkey.com\/sq\/alzheimer-blood-test\/","title":{"rendered":"Alzheimer&#8217;s Blood Test 2026: FDA-Approved Early Detection"},"content":{"rendered":"<p class=\"wp-block-paragraph\">For decades, diagnosing Alzheimer&#8217;s disease required invasive PET scans or painful lumbar punctures \u2014 and even then, primary care doctors were correct only about <strong>61% of the time<\/strong>. That has changed. As of May 2025, the FDA approved the first <strong>Alzheimer&#8217;s blood test<\/strong>, with a second test cleared in October 2025, transforming early detection forever.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This evidence-based 2026 guide walks you through every FDA-approved Alzheimer&#8217;s blood test, how they work, what they cost, and what they mean for the nearly <strong>7 million Americans<\/strong> living with the disease today.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Quick Answer<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">E <strong>Alzheimer&#8217;s blood test<\/strong> measures key biomarkers \u2014 primarily phosphorylated tau (pTau217 or pTau181) and the amyloid-beta 42\/40 ratio \u2014 to detect amyloid plaque buildup in the brain with over <strong>90% accuracy<\/strong>. The FDA approved the first such test, <strong>Lumipulse<\/strong>, in May 2025, followed by <strong>Elecsys pTau181<\/strong> in October 2025. Tests are approved for adults aged 55+ with cognitive symptoms and cost between $227 and $1,450 depending on the assay.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pikat kryesore<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA approval:<\/strong> Lumipulse (May 2025) and Elecsys pTau181 (October 2025) are now FDA-cleared for clinical use.<\/li>\n\n\n\n<li><strong>Accuracy:<\/strong> FDA-approved tests achieve 90%+ accuracy \u2014 far better than the 61% rate of primary-care clinical evaluation alone.<\/li>\n\n\n\n<li><strong>Who can use it:<\/strong> Adults aged 55+ with cognitive symptoms; not yet approved as a population-wide screening tool.<\/li>\n\n\n\n<li><strong>How it works:<\/strong> Detects amyloid-beta and pTau proteins linked to Alzheimer&#8217;s brain pathology \u2014 from a simple blood draw.<\/li>\n\n\n\n<li><strong>Cost range:<\/strong> $227 (Labcorp pTau-217) to $1,450 (PrecivityAD2). Insurance coverage is expanding rapidly post-approval.<\/li>\n\n\n\n<li><strong>Why it matters:<\/strong> Early detection enables earlier treatment with new disease-modifying drugs like lecanemab and donanemab.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Understanding Alzheimer&#8217;s Disease in 2026<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Alzheimer&#8217;s is a progressive brain disorder caused by the buildup of toxic <strong>amyloid-beta (A\u03b2)<\/strong> proteins and abnormal <strong>tau tangles<\/strong> in the brain. It is the most common cause of dementia, accounting for <strong>60\u201380%<\/strong> of all dementia cases.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Scale of the Problem<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>7 million Americans<\/strong> currently live with Alzheimer&#8217;s (Alzheimer&#8217;s Association, 2024)<\/li>\n\n\n\n<li>That number is projected to <strong>nearly double by 2060<\/strong><\/li>\n\n\n\n<li>Globally, <strong>40\u201350 million people<\/strong> are affected<\/li>\n\n\n\n<li>Over <strong>90%<\/strong> of those diagnosed are aged 65 or older<\/li>\n\n\n\n<li>Brain changes can begin <strong>up to 20 years before symptoms<\/strong> appear<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Early Warning Signs<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Persistent memory loss that disrupts daily life<\/li>\n\n\n\n<li>Difficulty solving problems or planning<\/li>\n\n\n\n<li>Confusion with time or place<\/li>\n\n\n\n<li>Trouble understanding visual images<\/li>\n\n\n\n<li>New problems with words in speaking or writing<\/li>\n\n\n\n<li>Misplacing things and losing the ability to retrace steps<\/li>\n\n\n\n<li>Changes in mood or personality<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Why Early Detection Matters More Than Ever<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The arrival of new disease-modifying Alzheimer&#8217;s drugs \u2014 like <strong>lecanemab (Leqembi)<\/strong> dhe <strong>donanemab (Kisunla)<\/strong> \u2014 has fundamentally changed the value of early diagnosis. These medications work best when amyloid plaques are caught early, before significant brain damage occurs.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8220;New medications are now available to treat Alzheimer&#8217;s disease, but they are only effective if it is diagnosed early, and early diagnosis depends on having accurate biomarkers.&#8221;<\/p>\n<cite>Dr. Abhay Moghekar, Johns Hopkins University School of Medicine<\/cite><\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">Benefits of Earlier Diagnosis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Access to FDA-approved <strong>amyloid-targeting therapies<\/strong><\/li>\n\n\n\n<li>Opportunity to participate in clinical trials<\/li>\n\n\n\n<li>Time to make legal, financial, and care planning decisions<\/li>\n\n\n\n<li>Lifestyle interventions that may slow progression<\/li>\n\n\n\n<li>Earlier emotional and family support planning<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The Timeline: A Diagnostic Revolution<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">2020\u20132024<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Early blood biomarker research at the University of Washington, Lund University, and Washington University in St. Louis lays the scientific foundation. PrecivityAD2 and SOBA tests show 90%+ accuracy in clinical studies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">May 2025<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">E <strong>FDA approves the first Alzheimer&#8217;s blood test<\/strong> \u2014 the Lumipulse G pTau217\/\u00df-Amyloid 1-42 Plasma Ratio by Fujirebio Diagnostics \u2014 for use in specialty settings.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">October 2025<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA approves the <strong>Elecsys pTau181 plasma test<\/strong> by Roche \u2014 the first Alzheimer&#8217;s blood test cleared specifically for use in primary care, helping doctors rule out Alzheimer&#8217;s as a cause of memory problems.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">2026 (current)<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Adoption accelerates as Medicare, private insurers, and global health systems begin expanding coverage. International availability grows rapidly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FDA-Approved Alzheimer&#8217;s Blood Tests Compared<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Test<\/th><th>Manufacturer<\/th><th>FDA Status<\/th><th>Use Case<\/th><th>Accuracy<\/th><\/tr><\/thead><tbody><tr><td><strong>Lumipulse G pTau217\/A\u03b242<\/strong><\/td><td>Fujirebio Diagnostics<\/td><td>Approved May 2025<\/td><td>Specialty care<\/td><td>90%+<\/td><\/tr><tr><td><strong>Elecsys pTau181<\/strong><\/td><td>Roche<\/td><td>Approved Oct 2025<\/td><td>Primary care (rule-out)<\/td><td>~90%<\/td><\/tr><tr><td><strong>PrecivityAD2<\/strong><\/td><td>C2N Diagnostics<\/td><td>FDA filing submitted<\/td><td>Clinical use (LDT)<\/td><td>88\u201392%<\/td><\/tr><tr><td><strong>ALZpath pTau217<\/strong><\/td><td>ALZpath \/ Labcorp<\/td><td>LDT (lab-developed)<\/td><td>Clinical use<\/td><td>88%<\/td><\/tr><tr><td><strong>AD-Detect<\/strong><\/td><td>Quest Diagnostics<\/td><td>LDT<\/td><td>Clinical use<\/td><td>Variable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">&#x1f4cc; <strong>What is an LDT?<\/strong> A Laboratory Developed Test is performed by a single CLIA-certified lab and doesn&#8217;t require full FDA approval before clinical use. Many Alzheimer&#8217;s blood tests are still LDTs in 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How the Blood Test Actually Works<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">The Science Behind the Test<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA-approved Alzheimer&#8217;s blood tests look for two key biomarkers strongly linked to brain pathology:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Amyloid-beta 42\/40 ratio (A\u03b242\/40)<\/strong> \u2014 A decreased ratio in blood indicates that amyloid is accumulating in the brain instead of being cleared into the bloodstream.<\/li>\n\n\n\n<li><strong>Phosphorylated tau (pTau217 or pTau181)<\/strong> \u2014 These modified tau proteins rise sharply as Alzheimer&#8217;s progresses, with pTau217 increasing by 300\u2013700% in symptomatic patients.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The Process: Step by Step<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Doctor consultation<\/strong> \u2014 Evaluate cognitive symptoms, medical history, and rule out other causes<\/li>\n\n\n\n<li><strong>Blood draw<\/strong> \u2014 A simple venous blood sample (the same as a routine blood test)<\/li>\n\n\n\n<li><strong>Lab analysis<\/strong> \u2014 Sample sent to a CLIA-certified lab for biomarker measurement (1\u20137 days)<\/li>\n\n\n\n<li><strong>Algorithmic interpretation<\/strong> \u2014 Results compared against validated cutoffs to predict amyloid pathology<\/li>\n\n\n\n<li><strong>Follow-up discussion<\/strong> \u2014 Doctor reviews results and discusses next steps (further testing, treatment, monitoring)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">Accuracy: How It Compares<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Diagnostic Method<\/th><th>Accuracy<\/th><\/tr><\/thead><tbody><tr><td>Primary care clinical evaluation (alone)<\/td><td>61%<\/td><\/tr><tr><td>Specialist memory clinic evaluation<\/td><td>73%<\/td><\/tr><tr><td>FDA-approved blood biomarker test<\/td><td><strong>90%+<\/strong><\/td><\/tr><tr><td>PET amyloid imaging<\/td><td>~95%<\/td><\/tr><tr><td>Cerebrospinal fluid (CSF) analysis<\/td><td>~95%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Cost and Insurance Coverage in 2026<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pricing varies considerably by test and lab. Following FDA approval, insurance and Medicare coverage is rapidly expanding for the approved tests.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Test<\/th><th>Out-of-Pocket Cost<\/th><th>Insurance Status (2026)<\/th><\/tr><\/thead><tbody><tr><td>Labcorp pTau-217<\/td><td><strong>$227<\/strong><\/td><td>Limited coverage; expanding<\/td><\/tr><tr><td>Quest AD-Detect<\/td><td><strong>$399<\/strong><\/td><td>Limited coverage<\/td><\/tr><tr><td>Labcorp ATN (A\u03b242\/40 + pTau-181 + NfL)<\/td><td><strong>$626<\/strong><\/td><td>Limited coverage<\/td><\/tr><tr><td>PrecivityAD<\/td><td><strong>$1,250<\/strong><\/td><td>Patient-assistance available<\/td><\/tr><tr><td>PrecivityAD2<\/td><td><strong>$1,450<\/strong><\/td><td>Patient-assistance available<\/td><\/tr><tr><td>Lumipulse (FDA-approved)<\/td><td>Variable<\/td><td>Medicare coverage expanding<\/td><\/tr><tr><td>Elecsys pTau181 (FDA-approved)<\/td><td>Variable<\/td><td>Medicare coverage expanding<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">&#x1f4a1; <strong>Insurance tip:<\/strong> FDA approval significantly improves the likelihood of insurance coverage. If your insurance denies coverage, ask your doctor about manufacturer patient-assistance programs \u2014 C2N Diagnostics and others offer financial assistance for qualifying patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Limitations and Important Caveats<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While groundbreaking, these tests are not perfect. Key limitations include:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">False Positives &amp; Negatives<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Even at 90%+ accuracy, ~10% of results may be incorrect<\/li>\n\n\n\n<li>PrecivityAD had a 23% false positive rate; PrecivityAD2 improved this to 11%<\/li>\n\n\n\n<li>Comorbid conditions (kidney disease, certain cancers) can affect biomarker levels<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">What the Test Does NOT Tell You<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>It does not give a definitive diagnosis on its own \u2014 it must be combined with clinical evaluation<\/li>\n\n\n\n<li>It does not predict <strong>when<\/strong> symptoms will appear or how quickly Alzheimer&#8217;s will progress<\/li>\n\n\n\n<li>It does not detect other forms of dementia (vascular, Lewy body, frontotemporal)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Who Should NOT Get the Test<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Asymptomatic adults seeking screening (not FDA-approved for this use)<\/li>\n\n\n\n<li>Adults under 55<\/li>\n\n\n\n<li>People without proper clinical evaluation by a qualified physician<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What This Means for Patients and Families<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Patient Perspective<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Surveys show <strong>72%<\/strong> of caregivers want to use blood tests for Alzheimer&#8217;s diagnosis, rising to <strong>92.5%<\/strong> when they learn that disease-modifying treatments are available. Early diagnosis enables families to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Access disease-modifying treatments at their most effective stage<\/li>\n\n\n\n<li>Make informed decisions about care, finances, and end-of-life planning<\/li>\n\n\n\n<li>Connect with support networks and counseling early<\/li>\n\n\n\n<li>Reduce diagnostic uncertainty and the emotional burden of not knowing<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Support Resources<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alzheimer&#8217;s Association 24\/7 Helpline:<\/strong> 1-800-272-3900<\/li>\n\n\n\n<li><strong>Care consultation services<\/strong> for personalized guidance<\/li>\n\n\n\n<li><strong>Local and virtual support groups<\/strong> for patients and caregivers<\/li>\n\n\n\n<li><strong>Memory walls and online communities<\/strong> for shared experiences<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Future Outlook: What&#8217;s Next<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The next few years will likely bring:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Broader insurance coverage<\/strong> as more FDA approvals come through<\/li>\n\n\n\n<li><strong>Expanded use in primary care<\/strong> as physicians receive training<\/li>\n\n\n\n<li><strong>Population-level screening<\/strong> may eventually become possible<\/li>\n\n\n\n<li><strong>Combination diagnostic panels<\/strong> integrating blood tests with AI and cognitive testing<\/li>\n\n\n\n<li><strong>New biomarkers<\/strong> for vascular dementia, Lewy body, and frontotemporal dementia<\/li>\n\n\n\n<li><strong>Faster turnaround times<\/strong> and reduced costs as adoption grows<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Concerned About Memory or Brain Health?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If you or a loved one is experiencing cognitive symptoms, early evaluation matters. Our neurology specialists in Turkey can help with comprehensive assessment, access to advanced diagnostics, and personalized treatment plans.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/wa.me\/905050157331\" rel=\"nofollow noopener\" target=\"_blank\">WhatsApp Us<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/revitalizeinturkey.com\/sq\/contact-us\/\">Free Consultation<\/a><\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Is the Alzheimer&#8217;s blood test FDA approved?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes. The FDA approved the first blood test (<strong>Lumipulse G pTau217\/\u00df-Amyloid 1-42 Plasma Ratio<\/strong>) in May 2025, followed by the <strong>Elecsys pTau181<\/strong> test in October 2025 for primary care use. Both are approved for adults 55+ with cognitive symptoms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How accurate is the Alzheimer&#8217;s blood test?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA-approved blood tests are <strong>over 90% accurate<\/strong> at detecting amyloid plaques associated with Alzheimer&#8217;s. The PrecivityAD2 test shows 88\u201392% accuracy, while traditional clinical evaluations were only 61% accurate in primary care settings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How much does an Alzheimer&#8217;s blood test cost?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Costs vary by test: <strong>Quest AD-Detect ($399)<\/strong>, <strong>Labcorp pTau-217 ($227)<\/strong>, <strong>Labcorp ATN ($626)<\/strong>, and <strong>PrecivityAD2 ($1,450)<\/strong>. Some FDA-approved tests are now beginning to receive Medicare and insurance coverage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Who should get an Alzheimer&#8217;s blood test?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA approval is for <strong>adults aged 55 and older who are already experiencing memory or cognitive symptoms<\/strong>. It is not currently recommended as a screening tool for people without symptoms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How does the Alzheimer&#8217;s blood test work?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The test measures key blood biomarkers \u2014 primarily <strong>phosphorylated tau (pTau217 or pTau181)<\/strong> and the <strong>amyloid-beta 42\/40 ratio<\/strong> \u2014 that correlate strongly with amyloid plaque buildup in the brain, a hallmark of Alzheimer&#8217;s disease.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can the blood test replace PET scans and spinal taps?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not entirely yet, but it can significantly reduce the need for them. The blood test is used to <strong>rule in or rule out<\/strong> Alzheimer&#8217;s biomarkers, helping doctors decide whether more invasive tests like PET scans or lumbar punctures are necessary.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How long does it take to get results?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Most blood test results are available within <strong>1\u20137 days<\/strong> after the lab receives the sample. Your doctor will then schedule a follow-up appointment to discuss results and next steps.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What if my test result is positive?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A positive result indicates a high likelihood of amyloid pathology \u2014 but it is not a definitive diagnosis. Your doctor will likely order additional testing (cognitive assessment, neurological exam, possibly imaging) and discuss treatment options including FDA-approved disease-modifying therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>Medical Disclaimer:<\/strong> This article is for informational purposes only and does not substitute professional medical advice. Always consult a qualified neurologist or healthcare provider for diagnosis and treatment decisions regarding Alzheimer&#8217;s disease and memory concerns. FDA approval status and insurance coverage information accurate as of May 2026.<\/em><\/p>\n<div class=\"sharing-default-minimal post-bottom\"><div class=\"nectar-social default\" data-position=\"\" data-rm-love=\"0\" data-color-override=\"override\"><div class=\"nectar-social-inner\"><a href=\"#\" class=\"nectar-love\" id=\"nectar-love-4966\" title=\"Love this\"> <i class=\"icon-salient-heart-2\"><\/i><span class=\"love-text\">Love<\/span><span class=\"total_loves\"><span class=\"nectar-love-count\">0<\/span><\/span><\/a><a class='facebook-share nectar-sharing' href='#' title='Share this'> <i class='fa fa-facebook'><\/i> <span class='social-text'>Share<\/span> <\/a><a class='twitter-share nectar-sharing' href='#' title='Share this'> <i class='fa icon-salient-x-twitter'><\/i> <span class='social-text'>Share<\/span> <\/a><a class='linkedin-share nectar-sharing' href='#' title='Share this'> <i class='fa fa-linkedin'><\/i> <span class='social-text'>Share<\/span> <\/a><a class='pinterest-share nectar-sharing' href='#' title='Pin this'> <i class='fa fa-pinterest'><\/i> <span class='social-text'>Pin<\/span> <\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>For decades, diagnosing Alzheimer&#8217;s disease required invasive PET scans or painful lumbar punctures \u2014 and even then, primary care doctors were correct only about 61% of the time. That has changed. As of May 2025, the FDA approved the first Alzheimer&#8217;s blood test, with a second test cleared in October 2025, transforming early detection forever. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_angie_page":false,"page_builder":"","footnotes":""},"categories":[7968],"tags":[8339,8338,8343,8345,1312,8347,8346,2414,8341,8337,8340,8344,8342],"class_list":["post-4966","post","type-post","status-publish","format-standard","hentry","category-mental-health-wellness","tag-alzheimer-blood-test","tag-alzheimers-disease","tag-amyloid-plaques","tag-biomarkers","tag-brain-health","tag-cognitive-decline","tag-dementia-diagnosis","tag-early-detection","tag-elecsys-ptau181","tag-fda-approved-blood-test","tag-lumipulse","tag-precivityad2","tag-tau-protein"],"_links":{"self":[{"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/posts\/4966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/comments?post=4966"}],"version-history":[{"count":1,"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/posts\/4966\/revisions"}],"predecessor-version":[{"id":64498,"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/posts\/4966\/revisions\/64498"}],"wp:attachment":[{"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/media?parent=4966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/categories?post=4966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revitalizeinturkey.com\/sq\/wp-json\/wp\/v2\/tags?post=4966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}